[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 235
Citations 0
Capitol Health Call
January 13, 2015

Senators Request Data About “Pay-for-Delay”

JAMA. 2015;313(2):124. doi:10.1001/jama.2014.17746

Sen Amy Klobuchar (D, Minn) and Sen Chuck Grassley (R, Iowa) urged the Federal Trade Commission (FTC) to promptly release the agency’s 2013 and 2014 reports about “pay-for-delay” settlements. Under such agreements, brand-name drug companies pay generic drug manufacturers to delay marketing their lower-cost products.

“Pay-for-delay agreements deny consumer access to more affordable alternatives to brand medications,” Klobuchar and Grassley, lead sponsors of the Preserve Access to Affordable Generics Act, wrote in a letter dated October 29 to FTC Chairwoman Edith Ramirez.

First Page Preview View Large
First page PDF preview
First page PDF preview
×